HYNOVA is a randomized clinical trial comparing the effects of chemotherapy drug given into the abdominal cavity at a temperature of 42°C (heated, HIPEC) versus 37°C (body temperature, NIPEC) at the end of surgery in patients with advanced cancer of the ovary, fallopian tube or peritoneum.

Trial Summary:

HYNOVA is a randomized clinical trial comparing the effects of chemotherapy drug given into the abdominal cavity at a temperature of 42°C (heated, HIPEC) versus 37°C (body temperature, NIPEC) at the end of surgery in patients with advanced cancer of the ovary, fallopian tube or peritoneum.

Supported By:

The University of Sydney, Australia New Zealand Gynaecological Oncology Group

Eligibility:

Patients with histologically or cytologically confirmed stage III epithelial OTP cancer following neoadjuvant chemotherapy with at least stable disease, undergoing interval CRS with residual disease of <2.5mm.

Registration ID:

ACTRN12621000269831

Participation:

Australia

Australian Lead Group:

Australia New Zealand Gynaecological Oncology Group

Status:

Recruiting

Activation Date:

September 2021

Chairs:

A/Prof Rhonda Farrell

Contact:

hynova.study@sydney.edu.au